After weeks of speculation, it’s official: GLP-1s will be part of TrumpRx.

Specifically, anti-obesity medications produced by Eli Lilly and Novo Nordisk will be available through TrumpRx for patients with Medicaid or Medicare, CNBC reports.¹ The deal includes existing medications and upcoming oral versions of the popular drugs.

How much will GLP-1 medications cost through TrumpRx?

President Trump announced the agreements at an Oval Office event on Thursday, November 6. These mark the latest high profile deals between the administration and major pharmaceutical companies.

According to the deal, injectable GLP-1 medications will be covered for certain Medicare patients, who will pay a copay of $50-a-month for the medication. This includes people who use the drugs for obesity or diabetes.

However, patients purchasing the medications through TrumpRx will face a charge of $350-a-month for Wegovy or Zepbound. According to the administration, that number will trend down to $245-per-month.

Both Eli Lilly and Novo Nordisk are working on oral GLP-1 medications, which will reportedly be available on the government-run DTC platform for $145-a-month. These medications will also be available for the same price through Medicare and Medicaid.

In response to the announcement, CNBC reports that Secretary Kennedy said, ““This is the biggest drug in our country, and that’s why this is the most important of all the [most favored nation] announcements we’ve made. This is going to have the biggest impact on the American people. All Americans, even those who are not on Medicaid, Medicare, are going to be able to get the same price for their drugs, for their GLP-1s.”

The list price for these medications can cost over $1,000-a-month, making the new agreement a significant deal for patients looking to get these medications. However, the listed prices for existing versions of Wegovy and Zepbound are still higher than numbers previously stated by President Trump.

In recent weeks, President Trump announced that weight-loss medications would be available for just $150-a-month through TrumpRx. However, administration officials quickly refuted these claims and clarified that talks were ongoing.

However, the President’s words still had an impact. Both Novo Nordisk and Eli Lilly reportedly faced questions from investors about the future profitability of these medications based on the pricing suggested by President Trump.

According to CNBC’s report, a senior administration official said that about 10% of Medicare beneficiaries would be eligible for GLP-1 medications through the government-run insurance program.

Novo Nordisk and Eli Lilly are the latest companies to announce partnerships with the Trump Administration. In September of this year, Pfizer became the first company to announce a deal.

At the time, Pfizer chairman and CEO Albert Bourla said, “We are proud to join President Trump at the White House to celebrate this landmark agreement that is a win for American patients, a win for American leadership, and a win for Pfizer. By working closely with the Administration, we are lowering costs for patients and enabling greater investment in the U.S. biopharmaceutical ecosystem by ending the days when American families alone carried the global burden of paying for innovation. This is about putting all patients first and ensuring America remains the world’s leading engine of medical breakthroughs.”

Sources

1. Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage. CNBC. November 6, 2025. https://www.cnbc.com/2025/11/06/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html